Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

Synthetic Biologics (SYN) Tops Q3 EPS by 3c

November 10, 2020 4:40 PM EST

Synthetic Biologics (NYSE: SYN) reported Q3 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17).

"During the third quarter, we remained sharply focused on executing our strategy to advance our portfolio of GI-focused clinical development programs while continuing to respond to the unprecedented global health and economic crisis sparked by the COVID-19 pandemic," said Steven A. Shallcross, Chief Executive and Financial Officer of Synthetic Biologics. "We were pleased to receive formal written notification from the U.S. Food and Drug Administration ("FDA") notifying the Company that the proposed Phase 1b/2a clinical study of SYN-004... More